Tranzyme bounces back from TPZ-102 trial failure with successful BMS research collaboration
This article was originally published in Scrip
Executive Summary
Tranzyme Pharma, a company developing mechanism-based therapeutics for the treatment of upper gastrointestinal (GI) motility disorders, has announced the successful completion of a chemistry-based drug discovery collaboration with New York-based biopharma, Bristol-Myers Squibb.